Observed relative risks of breast cancer after 5 years of use (RR5s) of estrogen-progestin therapy by progestin schedule (Lee et al. 2005)
In these regimens, the same daily dose of NETA, 1 mg, is used
with both the sequential and the continuous-combined EPT, so that
the total NETA dose per cycle is roughly 10 mg and 28 mg,
respectively, and the increased risk from the continuous-combined
regimen in Scandinavia is much greater than the increased risk seen
with the sequential regimen (Table 5 ; an 88% and 40%
Some of the greater effects seen within the sequential regimens in
Scandinavia compared to the United States (Table 5 ; 40% and
32% increase respectively) may be due to a greater effect of
NETA at 1 mg/day compared to 10 mg/day of MPA, although
these doses are generally considered equivalent based on their
endometrial effects (Stanczyk 2002).
Viewing this image requires a subscription. If you are a subscriber, please log in.
This table is from the chapter titled "Estrogens, Progestins, and Risk of Breast Cancer"
(from Progestins and the Mammary Gland), which is copyrighted by Springer-Verlag. For more information on the
copyright for this table, please refer to the full table caption and to the
The image is being made available for non-commercial purposes for subscribers to SpringerImages. For more information on what you are allowed to do with this image, please see our copyright policy.
To request permissions to use any copyrighted material, please visit the source document.
Report a copyright concern regarding this image.
Log in or register to save your favorite images and download them as high-quality PowerPoint or PDF files.
Log in or register to save your search criteria.
© Springer, part of Springer Science+Business Media.
Remote Address: 184.108.40.206 Server: 18